Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis

Sponsor

Redx Pharma Plc (Industry)

Overall Status

Recruiting

CT.gov ID

NCT05570058

Collaborator

Simbec Research (Industry)

Enrollment

Locations

Arms

18.8

Anticipated Duration (Months)

2.6

Patients Per Site

0.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of the study is to assess the safety and tolerability of RXC007 when given for 12 weeks (84 days), alone and in combination with nintedanib or pirfenidone.

Condition or Disease	Intervention/Treatment	Phase
IPF Fibrosis	Drug: RXC007 Drug: Placebo	Phase 2

Detailed Description

The purpose of this study is to investigate the study drug RXC007.

The main objectives of this study are as follows:

To determine the safety and tolerability (degree to which side effects of a drug can be tolerated) of RXC007 when it is administered as twice daily doses over a period of up to 12 weeks (84 days).
To investigate the concentration of RXC007 (how much drug is in your blood), how this changes over a period of time and to evaluate whether there are differences in the concentration between different dose strengths of RXC007.
To investigate the effect of RXC007 on the body (known as pharmacodynamics) by analysing the levels of certain biomarkers in the body and to assess the effect of RXC007 on markers associated with Idiopathic Pulmonary Fibrosis (IPF). Biomarkers are markers within the body such as a molecule or compound made by cells in the body, which can be measured and used to identify a particular disease.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

64 participants

Allocation:

Randomized

Intervention Model:

Sequential Assignment

Masking:

Triple (Participant, Investigator, Outcomes Assessor)

Primary Purpose:

Treatment

Official Title:

A Multi-Cohort, Randomised, Placebo-Controlled Phase 2a Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Ascending Doses of RXC007 in Patients With Idiopathic Pulmonary Fibrosis

Actual Study Start Date :

Sep 8, 2022

Anticipated Primary Completion Date :

Dec 1, 2023

Anticipated Study Completion Date :

Apr 1, 2024

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Cohort 1 12:4 (RXC007 : Placebo) Dose level 1: 12 weeks (84 days) dosing	Drug: RXC007 RXC007 will be administered in the form of oral capsules at 3 dose levels: 20 mg, 50mg and 70 mg in 5 cohorts. 12 patients of cohorts 1, 2 and 3 will receive RXC007 and 6 patients of cohorts 1B and 3B. The Dosage regimen is BID or QD. Drug: Placebo The placebo will be administered in the form of oral capsules at each dose level to 4 of the 16 participants within cohorts 1, 2 and 3. In Cohorts 1B and 3B, the placebo will be received by 2 of the 8 patients. The Dosage regimen is BID or QD
Experimental: Cohort 2 12:4 (RXC007 : Placebo) Dose level 2: 12 weeks (84 days) dosing	Drug: RXC007 RXC007 will be administered in the form of oral capsules at 3 dose levels: 20 mg, 50mg and 70 mg in 5 cohorts. 12 patients of cohorts 1, 2 and 3 will receive RXC007 and 6 patients of cohorts 1B and 3B. The Dosage regimen is BID or QD. Drug: Placebo The placebo will be administered in the form of oral capsules at each dose level to 4 of the 16 participants within cohorts 1, 2 and 3. In Cohorts 1B and 3B, the placebo will be received by 2 of the 8 patients. The Dosage regimen is BID or QD
Experimental: Cohort 3 12:4 (RXC007 : Placebo) Dose level 3: 12 weeks (84 days) dosing	Drug: RXC007 RXC007 will be administered in the form of oral capsules at 3 dose levels: 20 mg, 50mg and 70 mg in 5 cohorts. 12 patients of cohorts 1, 2 and 3 will receive RXC007 and 6 patients of cohorts 1B and 3B. The Dosage regimen is BID or QD. Drug: Placebo The placebo will be administered in the form of oral capsules at each dose level to 4 of the 16 participants within cohorts 1, 2 and 3. In Cohorts 1B and 3B, the placebo will be received by 2 of the 8 patients. The Dosage regimen is BID or QD
Experimental: Cohort 1B 16:2 (RXC007 : Placebo) Dose level 1; 12 weeks (28 days) dosing, Pre- and on-treatment bronchoscopy	Drug: RXC007 RXC007 will be administered in the form of oral capsules at 3 dose levels: 20 mg, 50mg and 70 mg in 5 cohorts. 12 patients of cohorts 1, 2 and 3 will receive RXC007 and 6 patients of cohorts 1B and 3B. The Dosage regimen is BID or QD. Drug: Placebo The placebo will be administered in the form of oral capsules at each dose level to 4 of the 16 participants within cohorts 1, 2 and 3. In Cohorts 1B and 3B, the placebo will be received by 2 of the 8 patients. The Dosage regimen is BID or QD
Experimental: Cohort 3B 16:2 (RXC007 : Placebo) Dose level 3; 12 weeks (28 days) dosing, Pre- and on-treatment bronchoscopy	Drug: RXC007 RXC007 will be administered in the form of oral capsules at 3 dose levels: 20 mg, 50mg and 70 mg in 5 cohorts. 12 patients of cohorts 1, 2 and 3 will receive RXC007 and 6 patients of cohorts 1B and 3B. The Dosage regimen is BID or QD. Drug: Placebo The placebo will be administered in the form of oral capsules at each dose level to 4 of the 16 participants within cohorts 1, 2 and 3. In Cohorts 1B and 3B, the placebo will be received by 2 of the 8 patients. The Dosage regimen is BID or QD

Outcome Measures

Primary Outcome Measures

Incidence and severity of AEs and SAEs Changes in safety laboratory parameters, vital signs, and ECGs [From Day 1 to post-study follow up visit (12 weeks)]
The primary endpoints of the study include the incidence and severity of AEs and SAEs
Number of participants who report a change from normal range values for laboratory safety parameters (serum biochemistry, serum haematology or urinalysis) from first dose on Day 1 to post-study follow up visit. [From Day 1 to post-study follow up visit (12 weeks)]
This primary endpoint will report the number of participants within all cohorts of study who record a value which is deemed as outside of the normal range (regardless of clinical significance) for any of the serum biochemistry, serum haematology or urinalysis parameters as defined in the study protocol following first dose administration on Day 1 up to completion of the post-study visit
Number of participants who report a change from normal range values for vital signs parameters (blood pressure, pulse rate, respiration rate, oral body temperature) from first dose on Day 1 to 12 weeks of treatment [From Day 1 to post-study follow up visit (12 weeks)]
This primary endpoint will report the number of participants within all cohorts of the study who record a value which is deemed as outside of the normal range (regardless of clinical significance) for any of the vital signs parameters (systolic/diastolic blood pressure, pulse rate, respiration rate, oral body temperature) as defined in the study protocol following first dose administration on Day 1 up to completion of the post-study visit
Number of participants who report a change from normal range values for any of the associated 12-Lead ECG parameters (heart rate, QT interval and QTcF interval) from first dose on Day 1 up to completion of the post-study visit. [From Day 1 to post-study follow up visit (12 weeks)]
This primary endpoint will report the number of participants within all cohorts of the study who record a value which is deemed as outside of the normal range (regardless of clinical significance) for any of the 12-Lead ECG parameters (heart rate, QT interval and QTcF interval) as defined in the study protocol following first dose administration on Day 1 up to 12 weeks of treatment

Secondary Outcome Measures

Pharmacokinetic Parameters - Maximum plasma concentration (Cmax) [For Cycle1 Day1 pre-dose, 1, 2, 3, 4, 8 h post-dose. For Cycle1 Day8 pre-dose, 1, 2, 3, 4, 8 h post-dose for all BID schedules. If the schedule is changed to QD, for Cycle1 Day8 will include a 24 h post-dose sample (Cycle1 Day9). On Cycle2 Day1 pre-dose.]
Plasma samples will be obtained in order to evaluate defined plasma pharmacokinetic parameters for RXC007. This endpoint will report the summary of derived pharmacokinetic parameters for the maximum observed concentration (Cmax) of RXC007 in plasma for all cohorts.
Minimum observed plasma concentration (Cmin) [For Cycle1 Day1 pre-dose, 1, 2, 3, 4, 8 h post-dose. For Cycle1 Day8 pre-dose, 1, 2, 3, 4, 8 h post-dose for all BID schedules. If the schedule is changed to QD, for Cycle1 Day8 will include a 24 h post-dose sample (Cycle1 Day9). On Cycle2 Day1 pre-dose.]
Plasma samples will be obtained in order to evaluate defined plasma pharmacokinetic parameters for RXC007. This endpoint will report the summary of derived pharmacokinetic parameters for the minimum observed concentration (Cmin) of RXC007 in plasma for all cohorts.
Pharmacokinetic Parameters - Time to maximum observed concentration (Tmax) [For Cycle1 Day1 pre-dose, 1, 2, 3, 4, 8 h post-dose. For Cycle1 Day8 pre-dose, 1, 2, 3, 4, 8 h post-dose for all BID schedules. If the schedule is changed to QD, for Cycle1 Day8 will include a 24 h post-dose sample (Cycle1 Day9). On Cycle2 Day1 pre-dose.]
Plasma samples will be obtained in order to evaluate defined plasma pharmacokinetic parameters for RXC007. This endpoint will report the summary of derived pharmacokinetic parameters for the time to maximum observed concentration (Tmax) of RXC007 in plasma for all cohorts.
Pharmacokinetic Parameters - Terminal elimination half-life (t1/2) [For Cycle1 Day1 pre-dose, 1, 2, 3, 4, 8 h post-dose. For Cycle1 Day8 pre-dose, 1, 2, 3, 4, 8 h post-dose for all BID schedules. If the schedule is changed to QD, for Cycle1 Day8 will include a 24 h post-dose sample (Cycle1 Day9). On Cycle2 Day1 pre-dose.]
Plasma samples will be obtained in order to evaluate defined plasma pharmacokinetic parameters for RXC007. This endpoint will report the summary of derived pharmacokinetic parameters for the terminal elimination half-life (t1/2) of RXC007 in plasma for all cohorts
Pharmacokinetic Parameters - Elimination rate constant (λz) [For Cycle1 Day1 pre-dose, 1, 2, 3, 4, 8 h post-dose. For Cycle1 Day8 pre-dose, 1, 2, 3, 4, 8 h post-dose for all BID schedules. If the schedule is changed to QD, for Cycle1 Day8 will include a 24 h post-dose sample (Cycle1 Day9). On Cycle2 Day1 pre-dose.]
Plasma samples will be obtained in order to evaluate defined plasma pharmacokinetic parameters for RXC007. This endpoint will report the summary of derived pharmacokinetic parameters for the elimination rate constant (λz) of RXC007 in plasma for all cohorts.
Pharmacokinetic Parameters - Area under the concentration-time curve (AUC) extrapolated to infinity (AUC0-inf) [For Cycle1 Day1 pre-dose, 1, 2, 3, 4, 8 h post-dose. For Cycle1 Day8 pre-dose, 1, 2, 3, 4, 8 h post-dose for all BID schedules. If the schedule is changed to QD, for Cycle1 Day8 will include a 24 h post-dose sample (Cycle1 Day9). On Cycle2 Day1 pre-dose.]
Plasma samples will be obtained in order to evaluate defined plasma pharmacokinetic parameters for RXC007. This endpoint will report the summary of derived pharmacokinetic parameters for the area under the concentration-time curve (AUC) extrapolated to infinity (AUC0-inf) of RXC007 in plasma for all cohorts.
Pharmacokinetic Parameters - Total apparent clearance following extravascular administration (CL/F) [For Cycle1 Day1 pre-dose, 1, 2, 3, 4, 8 h post-dose. For Cycle1 Day8 pre-dose, 1, 2, 3, 4, 8 h post-dose for all BID schedules. If the schedule is changed to QD, for Cycle1 Day8 will include a 24 h post-dose sample (Cycle1 Day9). On Cycle2 Day1 pre-dose.]
Plasma samples will be obtained in order to evaluate defined plasma pharmacokinetic parameters for RXC007. This endpoint will report the summary of derived pharmacokinetic parameters for the total apparent clearance following extravascular administration (CL/F) of RXC007 in plasma for all cohorts.
Pharmacokinetic Parameters - Apparent volume of distribution following extravascular administration (Vz/F) [For Cycle1 Day1 pre-dose, 1, 2, 3, 4, 8 h post-dose. For Cycle1 Day8 pre-dose, 1, 2, 3, 4, 8 h post-dose for all BID schedules. If the schedule is changed to QD, for Cycle1 Day8 will include a 24 h post-dose sample (Cycle1 Day9). On Cycle2 Day1 pre-dose.]
Plasma samples will be obtained in order to evaluate defined plasma pharmacokinetic parameters for RXC007. This endpoint will report the summary of derived pharmacokinetic parameters for the apparent volume of distribution following extravascular administration (Vz/F) of RXC007 in plasma for all cohorts.
Pharmacokinetic Parameters - Area under the plasma concentration-time curve during a dosing interval at steady state (AUCss) [For Cycle1 Day1 pre-dose, 1, 2, 3, 4, 8 h post-dose. For Cycle1 Day8 pre-dose, 1, 2, 3, 4, 8 h post-dose for all BID schedules. If the schedule is changed to QD, for Cycle1 Day8 will include a 24 h post-dose sample (Cycle1 Day9). On Cycle2 Day1 pre-dose.]
Plasma samples will be obtained in order to evaluate defined plasma pharmacokinetic parameters for RXC007. This endpoint will report the summary of derived pharmacokinetic parameters for the area under the concentration-time curve (AUC) at steady state of RXC007 in plasma for all cohorts.
% predicted and absolute volume change from baseline in Forced Vital Capacity (FVC) at 12 weeks [central review] [At Screening (Day28 to Day-1), Cycle1 Day1 pre-dose and post-dose, Cycle1 Day8, Cycle1 Day15, Cycle1 Day22, Cycle2 Day1(The day after Cycle1 Day28), Cycle2 Day15, Cycle3 Day1, Cycle3 Day28, End Of Treatment: last day of the dosing Day 21]
Information on Forced Vital Capacity (FVC) for the 6 months prior to study entry will be collected. Spirometry testing (without bronchodilator use) will be performed at all scheduled study visits in clinic. For each patient, spirometry testing should be conducted at approximately the same time of day.
% predicted and absolute change from baseline in carbon monoxide diffusion capacity (DLCO) [At Screening (day28 to Day-1), Cycle1 Day1 pre-dose, Cycle1 Day15, Cycle2 Day1 (The day after Cycle1 Day28)]
Carbon monoxide diffusion capacity will be measured in clinic

Eligibility Criteria

Criteria

Ages Eligible for Study:

40 Years to 80 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Aged ≥40 to 80 years at the time of signing the informed consent.
Diagnosis of IPF within 5 years of Screening based on the modified ATS/ERS/JRS/ALAT IPF guidelines for diagnosis and management of IPF (Raghu et al, 2018) and confirmed on independent central imaging review.
Combination of HRCT pattern, as assessed by central reviewers, consistent with diagnosis of IPF (see the modified ATS/ERS/JRS/ALAT IPF guidelines [Raghu et al, 2018]).
FVC % predicted ≥50% predicted of normal at Screening, with no clinically significant deterioration between the Screening Visit and randomisation, as determined by the Investigator.
DLco (Hb-adjusted) at screening ≥30%.
In the main study, participants receiving treatment for IPF with nintedanib or pirfenidone are allowed if on treatment for at least 3 months and on a stable dose for at least 4 weeks prior to Screening and during Screening.
In patients who are not on any treatment for IPF but have previously received nintedanib or pirfenidone, there needs to be a washout period ≥4 weeks prior to Screening.
No clinically significant abnormalities, in the opinion of the investigator, in vital signs (e.g., blood pressure, pulse rate, respiration rate, oral temperature) within 28 days before first dose of IMP.

Exclusion Criteria:

Currently receiving or planning to initiate treatment for IPF with agents not approved for that indication.
FEV1/FVC ratio <0.7 at Screening, pre-bronchodilator use.
Lower respiratory tract infection requiring antibiotics within 4 weeks of Screening or during Screening.

The extent of emphysema in the lungs exceeds fibrosis, based on central review of HRCT scans.

Need for continuous oxygen supplementation, defined as >15 hours/day.
Acute IPF exacerbation within 6 months of Screening or during Screening.
Clinical diagnosis of any connective-tissue disease (including, but not limited to, scleroderma, polymyositis/dermatomyositis, systemic lupus erythematosus, and rheumatoid arthritis) or a diagnosis of interstitial pneumonia with autoimmune features as determined by the Investigator applying the recent ERS/ATS research statement [Fischer et al 2015]. Note: Serological testing is not needed if not clinically indicated.
Disease other than IPF with a life expectancy of less than 12 weeks.

Additional exclusion criteria for the Translational Science Sub Study

Participants with any contra-indication to bronchoscopy and alveolar lavage including tracheal stenosis, pulmonary hypertension, severe hypoxia, or hypercapnia.
Patients in the sub study are not permitted to receive nintedanib or pirfenidone within 3 weeks of randomisation and throughout the Treatment period. (Note: background IPF treatment should not be stopped for the purpose of eligibility)

Contacts and Locations

Locations

	Site	City	Country	Postal Code
1	E 502 PNE UZ Leuven	Leuven	Belgium	3000
2	CHU De Liège	Liège	Belgium	4000
3	Pneumologicka klinika 1.LF UK a	Praha	Czechia	140 59
4	Azienda Ospedaliero-Universitaria "Ospedali-Riuniti" di Ancona	Ancona	Italy	60126
5	Azienda Ospedaliero Universitaria Policlinico ''G.Rodolico-San Marco''	Catania	Italy	95123
6	Colonello D'avanzo Hospital	Foggia	Italy	71122
7	PO Vito Fazzi	Lecce	Italy	73100
8	Azienda Ospedaliera Universitaria of Modena	Modena	Italy	41124
9	Fondazione Policlinico Universitario A. Gemelli	Roma	Italy	00168
10	Azienda Ospedaliera Universitaria Integrata Verona	Verona	Italy	37126
11	Policlinica Barcelona	Barcelona	Spain	08006
12	Hospital Universitario Clínic de Barcelona	Barcelona	Spain	08036
13	L'Hospital Universitari de Bellvitge	Barcelona	Spain	08907
14	Hospital Clínico San Carlos	Madrid	Spain	28040
15	Hospital Universitario La Paz	Madrid	Spain	28046
16	Hospital Universitario Central de Asturias	Oviedo	Spain	33011
17	Hospital Universitario Marqués de Valdecilla	Santander	Spain	39008
18	Hospital Clínico Universitario de Santiago de Compostela	Santiago De Compostela	Spain	15706
19	Queen Elizabeth Hospital	Birmingham	United Kingdom	B15 2GW
20	Royal Papworth Hospital NHSFT	Cambridge	United Kingdom	CB2 0AY
21	Royal Infirmary of Edinburgh	Edinburgh	United Kingdom	EH16 4SA
22	Guy's Hospital	London	United Kingdom	SE1 9RT
23	Royal Brompton Hospital	London	United Kingdom	SW3 6HP
24	Churchill Hospital, Oxford University Hospitals NHS Trust	Oxford	United Kingdom	OX7 3LE
25	University Hospital Southampton NHS Foundation Trust	Southampton	United Kingdom	SO16 6YD

Sponsors and Collaborators

Redx Pharma Plc
Simbec Research

Investigators

Principal Investigator: Philip Molyneaux, MD, Royal Brompton & Harefield NHS Foundation Trust
Principal Investigator: Toby Maher, MD, University of Southern California, USA